Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
The goal of this observational study is to learn about how Pristiq is currently being used in
 general practice and how psychiatrists and primary care physicians currently perceive Pristiq
 in terms of efficacy, tolerability, and adherence compared to other treatments for major
 depressive disorder (MDD).
It is retrospective patient chart study among psychiatrists and primary care physicians
 (PCPs) treating patients suffering from major depressive disorder (MDD). Physicians will be
 asked general medical questions in order to quantify their prescribing behavior and their
 perception of treatment performance. A retrospective patient chart review will then be
 performed and patient data will be collected to document patient characteristics and actual
 treatment outcomes. Upon qualification, specific instructions for chart review will be
 provided. Once the identified charts are pulled, the physicians are instructed to continue
 with the on-line survey. In total, there will be approximately 450 psychiatrists and 450
 primary care physicians participating in this trial.
Inclusion Criteria:

 -  Patients must be adult, diagnosed with major depressive disorder and treated with
 pharmacotherapy.

 -  Physicians must be either a psychiatrist or a primary care physician, a prescriber of
 Pristiq, have at least 3 charts representing the 4 identified patient types, have been
 in clinical practice between 4 and 35 years, primarily office based (50%+), not
 participated in a research study relating to antidepressants or antidepressant therapy
 within the past month, not a consultant or have a professional relationship with a
 pharmaceutical company other than for clinical trials or speaking engagements, and not
 be employed by of affiliated with an advertising agency, market research company, or
 pharmaceutical company.

 Exclusion Criteria:

 -  Patients who have not been treated for depression.